Acute HIV-1 infection viremia associate with rebound upon treatment interruption.

[1]  Bethany L. Dearlove,et al.  Timing HIV infection with a simple and accurate population viral dynamics model , 2021, Journal of the Royal Society Interface.

[2]  D. Reeves,et al.  Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions. , 2020, AIDS reviews.

[3]  Bernd Weissmuller,et al.  Trials , 2020, Israelpolitik.

[4]  Jerome H. Kim,et al.  A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection , 2020, Journal of virus eradication.

[5]  H. Schuitemaker,et al.  Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption , 2020, Nature Medicine.

[6]  Bethany L. Dearlove,et al.  Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound , 2020, The Journal of clinical investigation.

[7]  A. d’Arminio Monforte,et al.  Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. , 2019, The Journal of antimicrobial chemotherapy.

[8]  A. Lazzarin,et al.  Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). , 2019, The Journal of antimicrobial chemotherapy.

[9]  J. Mascola,et al.  Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. , 2019, The lancet. HIV.

[10]  B. Walker,et al.  Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. , 2019, The lancet. HIV.

[11]  B. Walker,et al.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.

[12]  Jerome H. Kim,et al.  Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection , 2018, Nature Medicine.

[13]  M. Proschan,et al.  A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection , 2017, Science Translational Medicine.

[14]  J. Ananworanich,et al.  Virologic failure is uncommon after treatment initiation during acute HIV infection , 2016, AIDS.

[15]  J. Ananworanich,et al.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART , 2016, EBioMedicine.

[16]  D. Kuritzkes,et al.  Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials , 2016, Journal of acquired immune deficiency syndromes.

[17]  Jerome H. Kim,et al.  Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.

[18]  G. Pantaleo,et al.  A case for preART-adjusted endpoints in HIV therapeutic vaccine trials. , 2016, Vaccine.

[19]  Jerome H. Kim,et al.  Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection , 2016, Journal of virus eradication.

[20]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[21]  J. Mellors,et al.  The need for treatment interruption studies and biomarker identification in the search for an HIV cure. , 2015, AIDS.

[22]  Jerome H. Kim,et al.  Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection , 2015, AIDS.

[23]  Jerome H. Kim,et al.  A novel acute HIV infection staging system based on 4th generation immunoassay , 2013, Retrovirology.

[24]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[25]  C. Rouzioux,et al.  Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.

[26]  Victor De Gruttola,et al.  Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection , 2011, AIDS.

[27]  M. Hirsch,et al.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment , 2009, AIDS.

[28]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[29]  N. Pantazis,et al.  Highly Active Antiretroviral Therapy Interruption: Predictors and Virological and Immunologic Consequences , 2006, Journal of acquired immune deficiency syndromes.

[30]  Matthew C Strain,et al.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.

[31]  T. Perneger,et al.  Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions , 2004, AIDS.

[32]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[33]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .